Celltrion, Institutional Investors Net Sell 103,045 Shares Over Last 5 Days... Stock Price at 285,000 KRW (-2.4%)

Published 13 Nov.2020 10:30(KST)

As of 10:30 AM on the 13th, Celltrion is trading at 285,000 KRW, down 2.4% from the previous day. The trading volume is 361,938 shares, which is about 37.12% of the previous day's volume. Celltrion is known as a manufacturer of protein and biopharmaceutical products.

On November 10, Minjeong Seon, a researcher at Hana Financial Investment, stated, "The Humira biosimilar, expected to receive approval in Europe in the first half of 2021, is anticipated to be officially launched in the second half of 2021. Therefore, production should begin in earnest from the first half of 2021 to secure safety stock. Regarding Remsima SC, unlike Truxima in the U.S., there are no objective indicators to expect strong performance in 2021. As a result, the market evidence is somewhat insufficient for us to expect Remsima SC to achieve high growth and large-scale sales in 2021." She set Celltrion's target price at 364,000 KRW.

Over the past five days, individual investors have net purchased 56,077 shares of Celltrion, while foreigners and institutions have net purchased 82,527 shares and net sold 103,045 shares, respectively.

※ Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automated article creation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.